Vaccines
GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs
GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment
FDA Approves Moderna’s Next-Generation Covid Vaccine With Limited Use for Most Healthy People
Moderna; FDA approval; mNexspike; next-generation Covid vaccine; vaccine restrictions; Covid-19; Spikevax; elderly; high-risk medical conditions; Omicron JN.1 variant
Moderna’s Next-Generation COVID Shot Gets FDA Backing With Usage Limitations
Moderna; COVID-19 vaccine; FDA approval; mNEXSPIKE; mRNA-1283; next-generation vaccine; respiratory virus season; age restriction; underlying conditions; vaccine efficacy
RFK Jr. Ends CDC Covid Vaccine Recommendations for Healthy Children and Pregnant Women
RFK Jr.; COVID-19 vaccine; recommendations; children; pregnant women; CDC; HHS Secretary; public health policy
Uncertainty Surrounds Moderna’s Next-Generation COVID Shot Amid Policy Changes
Moderna; COVID-19 vaccine; FDA policy; combination flu/COVID-19 shot; vaccine access; mRNA-1083; vaccine recommendations; regulatory setback
FDA Expects ‘Timely Availability’ of Covid Shots as Advisors Update Formula Recommendation
FDA; Covid-19; vaccine; formula update; timely availability; advisory committee; JN.1-lineage; KP.2 strain; 2025-2026
Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application
Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price
Vinay Prasad’s First Major Policy: Challenging Covid Vaccine ‘Dogma’ at FDA
Vinay Prasad; FDA; Covid-19 vaccines; policy change; clinical trials; vaccine recommendations; public health; regulatory framework
FDA Institutes Stricter, Targeted COVID Vaccine Policy, Moving Away from ‘One-Size-Fits-All’ Approach
FDA; COVID-19; vaccine policy; vaccine eligibility; clinical trials; high-risk groups; elderly; policy change; public health
FDA Approves Novavax COVID Vaccine After Delay, Limits Use to Smaller High-Risk Population
Novavax; FDA approval; COVID-19 vaccine; Nuvaxovid; restricted population; protein-based vaccine; older adults; underlying health conditions